Goldman Sachs
DNTH icon

Goldman Sachs’s Dianthus Therapeutics DNTH Stock Holding History

Goldman Sachs’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.3M Sell
382,161
-165,849
-30% -$14.5M ﹤0.01% 2060
2026
Q1 		$46M Sell
548,010
-29,009
-5% -$1.68M 0.01% 1646
2025
Q4 		$23.8M Buy
577,019
+358,248
+164% +$13.9M ﹤0.01% 2221
2025
Q3 		$8.61M Sell
218,771
-145,821
-40% -$3.73M ﹤0.01% 3109
2025
Q2 		$6.79M Buy
364,592
+291,162
+397% +$5.46M ﹤0.01% 3125
2025
Q1 		$1.33M Sell
73,430
-134,637
-65% -$2.97M ﹤0.01% 4479
2024
Q4 		$4.54M Buy
208,067
+127,461
+158% +$3.28M ﹤0.01% 3539
2024
Q3 		$2.21M Buy
80,606
+38,737
+93% +$1.08M ﹤0.01% 4076
2024
Q2 		$1.08M Sell
41,869
-128,348
-75% -$3.09M ﹤0.01% 4373
2024
Q1 		$5.11M Buy
+170,217
New +$3.7M ﹤0.01% 3070
2023
Q1 		– Sell
-2,379
Closed -$15K – 5985
2022
Q4 		$15K Sell
2,379
-4,606
-66% -$81.5K ﹤0.01% 5726
2022
Q3 		$158K Sell
6,985
-664
-9% -$18.2K ﹤0.01% 5557
2022
Q2 		$147K Sell
7,649
-2,481
-24% -$61.3K ﹤0.01% 5741
2022
Q1 		$470K Sell
10,130
-1,559
-13% -$85.2K ﹤0.01% 5356
2021
Q4 		$829K Buy
11,689
+947
+9% +$95.2K ﹤0.01% 5008
2021
Q3 		$1.25M Buy
10,742
+1,165
+12% +$136K ﹤0.01% 4574
2021
Q2 		$1.5M Buy
9,577
+5,728
+149% +$1.05M ﹤0.01% 4452
2021
Q1 		$730K Sell
3,849
-998
-21% -$168K ﹤0.01% 4847
2020
Q4 		$608K Sell
4,847
-1,043
-18% -$118K ﹤0.01% 4497
2020
Q3 		$641K Buy
5,890
+1,078
+22% +$128K ﹤0.01% 4346
2020
Q2 		$578K Buy
4,812
+2,132
+80% +$300K ﹤0.01% 4293
2020
Q1 		$269K Buy
2,680
+1,283
+92% +$238K ﹤0.01% 4572
2019
Q4 		$339K Buy
1,397
+20
+1% +$3.74K ﹤0.01% 4697
2019
Q3 		$226K Sell
1,377
-140
-9% -$26.6K ﹤0.01% 4780
2019
Q2 		$358K Sell
1,517
-234
-13% -$57.9K ﹤0.01% 4534
2019
Q1 		$461K Buy
1,751
+605
+53% +$104K ﹤0.01% 4456
2018
Q4 		$105K Buy
+1,146
New +$156K ﹤0.01% 4987
2018
Q3 		– Sell
-4,719
Closed -$1.02M – 5599
2018
Q2 		$1.02M Buy
+4,719
New +$1.07M ﹤0.01% 4057

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Goldman Sachs's DNTH Position: Q2 2026 in Review

Goldman Sachs reduced its Dianthus Therapeutics (DNTH) stake by 30% in Q2 2026, selling an estimated $14.5M and leaving 382,161 shares worth $37.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2060.

Goldman Sachs first reported a position in DNTH in Q2 2018 and has held it in 28 quarters since. The position peaked at $46M in Q1 2026. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Goldman Sachs held 382,161 shares of Dianthus Therapeutics worth $37.3M as of Q2 2026.
  • Goldman Sachs sold 165,849 Dianthus Therapeutics shares in Q2 2026, an estimated $14.5M.
  • Dianthus Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2060 holding.
  • Goldman Sachs first reported a position in Dianthus Therapeutics in Q2 2018 and has held it in 28 quarters since.
  • Goldman Sachs's Dianthus Therapeutics position peaked at $46M in Q1 2026.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.